Home > Resources > Company Profiles > GlaxoSmithKline PLC > News

GlaxoSmithKline PLC (GSK)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Andrew Witty , Divisional President/Director/CEO

www.gsk.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company and its subsidiary is engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products.

Portfolio Articles

Just What the Doctor Ordered
GlaxoSmithKline and Eli Lilly break with the rest of the drug industry on pricing and on disclosing studies and doctors' perks.
May 21 2008
The Ultimare Cure
The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed.
May 12 2008
Fountain of Money
Sirtris Pharmaceuticals and its novel drugs to combat age-related diseases and to increase life span are snatched up by GlaxoSmithKline for $720 million.
Apr 23 2008
Dollar Daze
Weakling currency is pummeling European companies in the U.S.
Oct 17 2007
Passing the Glaxo Drug Test
Pharmaceutical giant picks its next C.E.O.
Oct 08 2007

See more news on this company

News Feeds

NPS shares fall as Glaxo pulls out of drug study AP
Sep 26 2008
Roche, GSK urge employers to stockpile flu drugs AP
Sep 26 2008
Glaxo ends study on NPS osteoporosis drug AP
Sep 26 2008
Molecular Insight names 4 directors to board AP
Sep 22 2008
Drug stocks rise with the markets Thursday morning AP
Sep 18 2008
Glaxo submits restless leg drug for FDA approval AP
Sep 16 2008
Drug maker stocks edge lower in morning trading AP
Sep 16 2008
GlaxoSmithKline consolidates cancer research AP
Sep 11 2008

Portfolio Blogs

Do Antidepressants Prevent Suicides?
Apr 10 2008

Press Releases

Genmab Reaches Milestone in Ofatumumab Collaboration Oct-10-2008, 11:16AM EDT
GlaxoSmithKline Executive Appointed to Chair NBPTS Advisory Committee Oct-02-2008, 10:10AM EDT
Celldex Receives $10 Million Milestone Payment Oct-02-2008, 08:00AM EDT
Zacks Analyst Blog Highlights: GlaxoSmithKline Plc., Metabasis Therapeutics, Inc., Central Garden & Pet Co., AFLAC Inc. and Crown Castle International Corp. Oct-01-2008, 06:00AM EDT
Research and Markets: Benchmark Glaxosmithkline, Assess the Threat Posed By Generic Competition and Analyze GSK's Future Strategic Direction Sep-30-2008, 02:37PM EDT

News From Around the Web

News

Drugs and Disclosure (New York Times)

Oct 11 2008
safety concerns about Avandia (Wall Street Journal Health Blog)

Oct 10 2008
Genmab says gets $5.6 mln milestone payment from Glaxo (Reuters)

Oct 10 2008
Investments to Beat the Financial Crisis (Motley Fool)

Oct 09 2008
Elephantiasis Elimination Program on Track (MedLine Plus)

Oct 09 2008
Canadian Vaccine Manufacturer Able to Deliver Doses Ahead of Schedule (Drugs.com)

Oct 09 2008
Possible Glaxo move might be a boon for tower project (Philadelphia Business Journal)

Oct 09 2008
'End in sight' for elephantiasis (BBC News)

Oct 08 2008
Eliminating elephantiasis (IOL, South Africa)

Oct 08 2008
LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease (Drugs.com)

Oct 08 2008

Blogs

A drug company, a psychiatrist, and an inexplicable failure to disclose conflicts of interest. (Adventures in Ethics and Science)

Oct 08 2008
What Rules? Emory Fiddled While Nemeroff Earned (Pharmalot)

Oct 05 2008

Employees

Number of Employees: 103,000

Revenue per Employee: $455,514

Top Executives

Marc Dunoyer, Divisional President

Eddie Gray, President, Divisional

Dr. Russell Greig, Divisional President

Julian Heslop, CFO/Director

John Clarke, Divisional President

Dan Phelan, Divisional Senior VP

Bill Louv, Chief Information Officer

Duncan Learmouth, Senior VP, Divisional

Christopher Viehbacher, Divisional President/Director

Dr. David Pulman, Divisional President

Board of Directors

Dr. Stephanie Burns, Ph.D., Director

Dr. Daniel Podolsky, Director

Sir Robert Wilson, Director

Simon Bicknell, Secretary

Sir Crispin Davis, Director

Sir Ian Prosser, Director

Sir Christopher Gent, Chairman of the Board/Director

Dr.Ronaldo H. Schmitz, Director

Dr. Moncef Slaoui, Ph.D., Chairman of the Board, Divisional/Director

Julian Heslop, CFO/Director

Tom de Swaan, Director

Lawrence Culp, Director

Sir Deryck Maughan, Director

Professor Sir Roy Anderson, Director

Christopher Viehbacher, Divisional President/Director

Financials

Quarterly

Annual

Income Statement	04/2008	02/2008	10/2007	07/2007
Sales	1.96 Bil.	2.49 Bil.	1.69 Bil.	1.92 Bil.
Gross Operating Profit	9.32 Bil.	9.37 Bil.	9.51 Bil.	9.47 Bil.
Operating Income before D & A (EBITDA)	4.36 Bil.	3.68 Bil.	4.63 Bil.	4.19 Bil.
Total Income Before Interest Expenses (EBIT)	4.09 Bil.	3.28 Bil.	4.09 Bil.	4.05 Bil.
Total Net Income	2.59 Bil.	2.1 Bil.	2.68 Bil.	2.68 Bil.
Basic EPS, Total	0.97	0.78	0.97	0.96
Diluted EPS, Total	0.97	0.78	0.97	0.95

BALANCE STATEMENT	04/2008	02/2008	10/2007	07/2007
Cash and Equivalents	4.26 Bil.	6.71 Bil.	4.19 Bil.	3.8 Bil.
Total Assets	24.86 Bil.	27.05 Bil.	23.28 Bil.	22.03 Bil.
Total Liabilities	18.4 Bil.	20.54 Bil.	18.47 Bil.	14.47 Bil.
Total Capitalization	33.78 Bil.	33.09 Bil.	30.2 Bil.	31.76 Bil.

Cash Flow	04/2008	02/2008	10/2007	07/2007
Net Cash From Continuing Operations	3.57 Bil.	12.23 Bil.	9.77 Bil.	5.89 Bil.
Net Cash From Investing Activities	-468 Mil.	-5.97 Bil.	-3.34 Bil.	-2.57 Bil.
Net Cash From Financing Activities	-5.6 Bil.	-3.46 Bil.	-6.61 Bil.	-3.66 Bil.
Net Change in Cash & Cash Equivalents	-2.51 Bil.	2.8 Bil.	-172 Mil.	-371 Mil.

Income Statement	2008	2007	2006	2005
Sales	7.91 Bil.	7.94 Bil.	6.64 Bil.	6.55 Bil.
Gross Operating Profit	37.18 Bil.	37.55 Bil.	30.62 Bil.	32.48 Bil.
Operating Income before D & A (EBITDA)	16.78 Bil.	16.57 Bil.	12.75 Bil.	13.5 Bil.
Total Income Before Interest Expenses (EBIT)	15.69 Bil.	15.89 Bil.	12.36 Bil.	12.32 Bil.
Total Net Income	10.35 Bil.	10.56 Bil.	8.07 Bil.	8.25 Bil.
Basic EPS, Total	3.75	3.74	3	2.88
Diluted EPS, Total	3.75	3.7	3	2.87

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	6.71 Bil.	3.93 Bil.	7.24 Bil.	2.23 Bil.
Total Assets	27.05 Bil.	21.53 Bil.	22.67 Bil.	26.14 Bil.
Total Liabilities	20.54 Bil.	14.23 Bil.	16.36 Bil.	16.72 Bil.
Total Capitalization	33.09 Bil.	27.54 Bil.	21.64 Bil.	19.76 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	12.23 Bil.	8.53 Bil.	10.25 Bil.	9.02 Bil.
Net Cash From Investing Activities	-5.97 Bil.	-2.98 Bil.	-2.86 Bil.	-2.12 Bil.
Net Cash From Financing Activities	-3.46 Bil.	-9.39 Bil.	-5.01 Bil.	-7.54 Bil.
Net Change in Cash & Cash Equivalents	2.8 Bil.	-4.33 Bil.	2.78 Bil.	-644 Mil.

GlaxoSmithKline PLC (GSK)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request